GSK receives European authorisation for once-weekly type 2 diabetes treatment, Eperzan® (albiglutide)
Issued: Wednesday 26 March 2014, London UK – LSE Announcement GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that the European Commission has granted marketing authorisation for its once-weekly diabetes treatment, Eperzan® (albiglutide). Eperzan is …